News | January 08, 2009

Bayer Schering Pharma Deal Targets Molecular Imaging

January 8, 2009 – Bayer Schering Pharma AG and Hamamatsu Photonics K.K., Japan have signed a licensing agreement for the use of novel substances in the field of molecular imaging for cancer, allowing the company to expand its existing molecular imaging portfolio in the area of cancer.

In the agreement, Bayer Schering Pharma acquires the worldwide exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells. The company anticipates that used in combination with positron emission tomography (PET), these tracers could potentially improve the diagnosis of a variety of cancers.

The tracers are labeled with a short-life radionuclide and thus can be employed for PET imaging. PET is a nuclear medicine imaging procedure, with which molecular processes can be visualized in vivo, for example those in tumor cells. In contrast to the presently common procedures in PET imaging of cancer, these new PET tracers could help to possibly better differentiate malignant tumors from benign tissue alterations and to allow a more precise staging of the cancer.

"We have developed the novel tumor PET tracer based on a substance to be incorporated into tumor cells through the carrier molecules highly expressed on the tumor cell membrane. Since the chemical structure of this PET tracer is designed not to be identified by the carrier system on the normal cell membrane, the location of tumor tissue could be detected with high contrast in tumor animal models with PET,” said Hideo Tsukada, M.D., manager of the PET Center at Hamamatsu Photonics.

Find more information: www.bayerhealthcare.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init